EFFERVESCENT ALCALOSE GRANULATE 30 BAGS 4gr
TECHNICAL SHEET RCP DRUGS FROM DATABASE
[su_spoiler title = "
MEDICINAL NAME"style =" fancy "icon =" chevron-circle "] ALKALOSE effervescent granulate. [/ su_spoiler]
[su_spoiler title = "
QUALITATIVE AND QUANTITATIVE COMPOSITION"style =" fancy "icon =" chevron-circle "]
100 g of granules contain:
Active ingredients: glucose 69.24 g; potassium citrate 1.00 g; pyridoxine hydrochloride 0.05 g.
For the full list of excipients, see section 6.1.
[su_spoiler title = "
PHARMACEUTICAL FORM"style =" fancy "icon =" chevron-circle "] Effervescent granulate. [/ su_spoiler]
[su_spoiler title = "
THERAPEUTIC INDICATIONS"style =" fancy "icon =" chevron-circle "] ALCALOSE is indicated:
Symptomatic treatment of gastric hyperacidity - Vomiting - States of acetonemia. [/ Su_spoiler]
[su_spoiler title = "
DOSAGE AND METHOD OF ADMINISTRATION"style =" fancy "icon =" chevron-circle "]
Jar 150 g
Adults: 2 teaspoons of coffee in a glass of water after meals or at the onset of symptoms.
The maximum daily dose is 2 teaspoons 3-4 times a day.
Children: 1 teaspoon, in a glass of water repeated during the day.
The maximum daily dose is 1 teaspoon 3-4 times a day.
4 g sachet
Adults: 2 sachets, in a glass of water, after meals or at the onset of symptoms.
The maximum daily dose is 2 sachets 3-4 times a day.
Children: 1 sachet, in a glass of water, repeatedly during the day.
The maximum daily dose is 1 sachet 3 - 4 times a day. [/ Su_spoiler]
[su_spoiler title = "
CONTRAINDICATIONS"style =" fancy "icon =" chevron-circle "] Hypersensitivity to the active ingredient (aceclofenac) States of hyperkalaemia. Hypersensitivity to the active ingredients or to any of the excipients. [/ su_spoiler]
[su_spoiler title = "
WARNINGS AND PRECAUTIONS FOR USE"style =" fancy "icon =" chevron-circle "] After a short period of treatment without appreciable results, consult your doctor.
The product contains potassium whose excessive intake must be avoided; therefore the drug should be taken at the recommended doses and the treatment should be prolonged only for the time necessary to control symptoms; in the case of repeated treatments, each cycle of therapy must be appropriately spaced from the previous one. The potassium content of the medicinal product should be taken into account in cases where a highly hypokalaemic diet is recommended, for example in the case of congestive heart failure and renal failure or in the case of taking drugs that increase plasma potassium levels.
Each dose (two coffee spoons equal to approximately 8 g, equal to 2 sachets) of ALKALOSE contains about 5.5 g of glucose and 0.8 g of sucrose, this should be taken into account in diabetic subjects or and in all conditions in which a low-calorie diet.
Patients with glucose / galactose malabsorption, fructose intolerance or sucrase-isomaltase insufficiency.
Important information about some of the excipients.
Each dose (two coffee spoons equal to approximately 8 g, equal to 2 sachets) of ALKALOSE contains approximately 145 mg of sodium; this should be taken into account in hypertensive subjects or in all conditions in which a low-sodium diet is required. [/ su_spoiler]
[su_spoiler title = "
INTERACTIONS"style =" fancy "icon =" chevron-circle "]
Antacids in general can interfere with the oral administration of other drugs by various mechanisms. It is possible to administer ALKALOSE only 1 hour before or 2 hours after taking other medications.
ALKALOSE can be taken regardless of meals. [/ Su_spoiler]
[su_spoiler title = "FERTILITY, PREGNANCY AND BREASTFEEDING"style =" fancy "icon =" chevron-circle "] Adequate and well controlled pregnancy studies have not been performed.
ALCALOSE can be used in pregnancy, at recommended doses and for short therapeutic cycles, only if the benefit justifies the potential risk to the fetus or child.
The components of ALKALOSE are excreted with milk. However, at therapeutic doses of ALKALOSE, no effects on breastfeeding are foreseeable. ALKALOSE can be used during breastfeeding. [/ Su_spoiler]
[su_spoiler title = "
EFFECTS ON THE ABILITY TO DRIVE VEHICLES"style =" fancy "icon =" chevron-circle "] No interference is known. [/ su_spoiler]
[su_spoiler title = "
SIDE EFFECTS"style =" fancy "icon =" chevron-circle "]
At the recommended doses no undesirable effects are reported. [/ Su_spoiler]
[su_spoiler title = "
OVERDOSE"style =" fancy "icon =" chevron-circle "] No data are available regarding overdosing in humans.
At the recommended doses and for short periods of treatment, the risk of excess potassium and sodium bicarbonate phenomena is non-existent. However, in the event of an overdose, treatment should be symptomatic with generic supportive measures. [/ Su_spoiler]
[su_spoiler title = "
LIST OF EXCIPIENTS"style =" fancy "icon =" chevron-circle "] Sodium citrate; Citric acid; Sodium bicarbonate; Sucrose. [/ su_spoiler]
[su_spoiler title = "
STORAGE"style =" fancy "icon =" chevron-circle "] Jar 150 g
Store at a temperature not exceeding 25 ° C; keep the container tightly closed; close immediately after use.
4 g sachet
Store at a temperature not exceeding 25 ° C. [Su_spoiler title = "
MARKETING AUTHORIZATION HOLDER"style =" fancy "icon =" chevron-circle "] Pharmaceutical Laboratory SIT Specialità Igienico Terapeutiche Srl - Via Cavour 70 - Mede (PV). [/ su_spoiler]
[su_spoiler title = "
AUTHORIZATION NUMBER - MINSAN"style =" fancy "icon =" chevron-circle "]
Jar 150 g AIC 020436 198
Sachet 4 g AIC 020436200. [/ Su_spoiler]
Convenient and safe payments
Shipping in 24h all over the world
Fast returns
Pharmaceutical experience
